New obesity drug MBX 4291 enters first human safety tests
NCT ID NCT07142707
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This early-stage study tests a new drug, MBX 4291, in 124 adults with obesity (BMI 30 to under 50) to see if it is safe and how the body handles it. Participants receive either the drug or a placebo as a shot under the skin. The main goal is to track any side effects, not to measure weight loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MBX Biosciences Investigational Site
RECRUITINGLexington, Kentucky, 40509, United States
-
MBX Biosciences Investigational Site
RECRUITINGKnoxville, Tennessee, 37920, United States
Conditions
Explore the condition pages connected to this study.